Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.77, with a volume of 1,120,717 shares.
Analyst Ratings Changes
Separately, Oppenheimer initiated coverage on Vaxart in a report on Thursday, August 15th. They issued an "outperform" rating and a $4.00 price objective on the stock.
Get Our Latest Report on Vaxart
Vaxart Stock Performance
The firm has a market cap of $136.60 million, a price-to-earnings ratio of -1.67 and a beta of 0.66. The company's 50-day moving average is $0.84 and its 200-day moving average is $0.77.
Vaxart (NASDAQ:VXRT - Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). The firm had revenue of $6.40 million during the quarter, compared to the consensus estimate of $65.70 million. Vaxart had a negative net margin of 543.21% and a negative return on equity of 114.19%. During the same period in the previous year, the company posted ($0.16) EPS. On average, analysts predict that Vaxart, Inc. will post -0.47 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in VXRT. Tidal Investments LLC bought a new position in shares of Vaxart during the first quarter worth approximately $56,000. Sequoia Financial Advisors LLC bought a new position in Vaxart during the 2nd quarter worth $65,000. Monaco Asset Management SAM acquired a new position in Vaxart in the 2nd quarter valued at $402,000. Millennium Management LLC lifted its position in shares of Vaxart by 110.8% during the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock valued at $2,660,000 after acquiring an additional 2,095,274 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock worth $10,984,000 after purchasing an additional 1,404,391 shares in the last quarter. 18.05% of the stock is owned by institutional investors and hedge funds.
Vaxart Company Profile
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Featured Stories
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
